However, notwithstanding the intriguing response to IL-1 blockade early in the disease course, it should be recalled that not all SJIA patients respond equally well to rIL-1RA therapy [25,30,31]. The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.